A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

A Randomized, Single-blind, Placebo-controlled, Phase 2 Trial Of The Safety, Immunogenicity, And Tolerability Of Meningococcal Serogroup B (Mnb) Rlp2086 Vaccine At Doses Of 60 Mug, 120 Mug, And 200 Mug In Healthy Adolescents Aged 11 To 18 Years

The purpose of this study is to evaluate the safety and immunogenicity of an investigational meningococcal B rLP2086 vaccine in adolescents aged 11 to 18 years old.

Inclusion Criteria:

• Healthy male or female subjects between the ages of >=11 and <=18 years at the time of enrollment.
• Negative urine pregnancy test for all female subjects.
• Parent/legal guardian or subject under supervision of the parent/legal guardian must be able to complete all relevant study procedures during study participation.

Exclusion Criteria:

• History of any invasive meningococcal disease.
• A previous anaphylactic or severe vaccine-associated adverse reaction.
• Any clinically significant chronic disease.
• A known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids. Topical, inhaled or intra-articular corticosteroids are allowed.
• Participation in another investigational study in the 1-month (30-day) period before study visit 1 and during the conduct of the study.